褚文玲, 符展豪, 俞贝贝. 20142021年浙江省余姚市居民恶性肿瘤死亡的流行病学特征[J]. 上海预防医学, 2023, 35(5): 433-439. DOI: 10.19428/j.cnki.sjpm.2023.22609
引用本文: 褚文玲, 符展豪, 俞贝贝. 20142021年浙江省余姚市居民恶性肿瘤死亡的流行病学特征[J]. 上海预防医学, 2023, 35(5): 433-439. DOI: 10.19428/j.cnki.sjpm.2023.22609
CHU Wenling, FU Zhanhao, YU Beibei. Epidemiological characteristics of malignant tumor mortality among residents in Yuyao from 2014 to 2021[J]. Shanghai Journal of Preventive Medicine, 2023, 35(5): 433-439. DOI: 10.19428/j.cnki.sjpm.2023.22609
Citation: CHU Wenling, FU Zhanhao, YU Beibei. Epidemiological characteristics of malignant tumor mortality among residents in Yuyao from 2014 to 2021[J]. Shanghai Journal of Preventive Medicine, 2023, 35(5): 433-439. DOI: 10.19428/j.cnki.sjpm.2023.22609

20142021年浙江省余姚市居民恶性肿瘤死亡的流行病学特征

Epidemiological characteristics of malignant tumor mortality among residents in Yuyao from 2014 to 2021

  • 摘要:
    目的 分析浙江省余姚市居民恶性肿瘤死亡水平及变化趋势,为恶性肿瘤人群精准防控提供支持。
    方法 收集2014—2021年余姚市户籍居民死亡监测数据,计算恶性肿瘤粗死亡率(CMR)、标化死亡率(SMR)、潜在减寿年数(PYLL)、平均减寿年数(AYLL)、潜在减寿年数率(PYLLR),利用Joinpoint回归模型计算平均年度变化百分比(AAPC)。
    结果 2014—2021年余姚市恶性肿瘤死亡13 754例,占同期全部死亡人数的26.54%,年均死亡率为205.63/10万,SMR为115.62/10万,8年间SMR呈下降趋势(AAPC=-4.76%,t=-2.296,P=0.061)。男性恶性肿瘤年均死亡率为274.15/10万,SMR为149.83/10万;女性恶性肿瘤年均死亡率为139.03/10万,SMR为81.01/10万,男性死亡率高于女性(χ2=1 487.389,P<0.001)。恶性肿瘤死亡率随年龄增长呈上升趋势(AAPC=54.94%,t=27.678,P<0.001)。8年间不同年龄组恶性肿瘤死亡率均呈现下降趋势(0~岁组AAPC=-5.74%,15~岁组AAPC=-8.49%,45~岁组AAPC=-6.02%,≥65岁组AAPC=-3.49%)。居民恶性肿瘤前5位死因分别是肺癌、胃癌、肝癌、食管癌和结直肠癌,占全部恶性肿瘤死亡人数的68.15%,肺癌位居男、女性恶性肿瘤死亡原因首位。恶性肿瘤死亡所致PYLL为96 585.50人年,AYLL为7.02年·人-1,PYLLR为16.42‰。
    结论 余姚市户籍居民恶性肿瘤死亡率呈下降趋势,但仍是威胁居民死亡的首要原因,肺癌是造成寿命损失最大的恶性肿瘤。建设起以男性、中老年人为重点对象,以健康生活方式为主,早期筛查、合理治疗阻断疾病进展相结合的恶性肿瘤综合干预体系刻不容缓。

     

    Abstract:
    Objective To determine the death level and change trend of malignant tumors among residents in Yuyao, and to provide support for accurate prevention and control of malignant tumors.
    Methods We collected the death monitoring data of Yuyao registered residents from 2014 to 2021, and calculated the indicators, including crude mortality rate (CMR), standardized mortality rate (SMR), potential years of life lost (PYLL), average years of life lost (AYLL), and PYLL rate (PYLLR). We also calculated the average annual change percentage (AAPC) using Joinpoint regression model.
    Results There were 13 754 deaths from malignant tumors in Yuyao from 2014 to 2021, accounting for 26.54% of the total deaths in the same period. The average annual mortality rate was 205.63/105, and the standardized mortality rate was 115.62/105. The SMR showed a downward trend in 8 years (AAPC=-4.76%, t=-2.296, P=0.061). The average annual mortality of malignant tumors was 274.15/105, and the standardized mortality was 149.83/105. The average annual mortality of female malignant tumors was 139.03/105, the standardized mortality was 81.01/105. Male mortality was higher than the female mortality (χ2=1 487.389, P<0.001).The mortality rate of malignant tumors increased with age (AAPC=54.94%,t=27.678,P<0.001). The mortality rate of malignant tumors in different age groups showed a downward trend in 8 years (AAPC=-5.74% for 0- years old group, -8.49% for 15- years old group, -6.02% for 45- years old group, and -3.49% for ≥65 years old group). The top five causes of death from malignant tumors in residents were lung cancer, gastric cancer, liver cancer, esophageal cancer and colorectal cancer, accounting for 68.15% of all deaths from malignant tumors. Lung cancer ranked first among the causes of death from male and female malignant tumors. PYLL caused by malignant tumor death was 96 585.50 person years, AYLL was 7.02 years per person, and PYLLR was 16.42‰.
    Conclusion The mortality rate of malignant tumors among registered residents in Yuyao is on the decline, but it is still the primary death cause threatening the residents. Lung cancer is the malignant tumor that causes the greatest loss of life. It is urgent to build a comprehensive intervention system for malignant tumors that focuses on men, middle-aged and elderly people, advocate a healthy lifestyle, and combine early screening and reasonable treatment to block disease progress.

     

/

返回文章
返回